Methods	Multicentre, randomised, double-blind, placebo-controlled, parallel-group. Single dose to treat single attack Medication administered when migraine headache pain was of moderate or severe intensity Assessments at 30, 60, 90, and 120 minutes after dosing Rescue medication was available after 30 minutes if there was no response to the study treatment
Participants	To be eligible for entry, participants were required to have a history of migraine (1 to 6 headaches a month) with or without aura as defined by the IHS (1988) No narcotic analgesics or ergotamine within the previous 24 h, or aspirin within the previous 6 h before study treatment N= 51 (50 for efficacy) M 7, F 43 (86%) Mean age 41 years Without aura 74%
Interventions	Sumatriptan 4 mg, n = 28 Placebo, n = 23 (22 for efficacy)
Outcomes	Only 30 minute efficacy outcomes reported Adverse events
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4.
Risk of bias
Bias	Authors’ judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Low risk	Matching placebo
Study size	High risk	Treatment groups <50 participants